The CDC has revised the U.S. childhood vaccine schedule, reducing the number of routine vaccinations from 17 to 11. This change, prompted by a presidential directive from the Trump administration, aligns U.S. recommendations with those of other developed nations. Vaccines for diseases like rotavirus and hepatitis A and B are now recommended only for high-risk…

The article discusses the potential of proactive healthcare to significantly reduce costs and improve health outcomes in the U.S. By shifting from a reactive to a proactive model, the U.S. could save $2.2 trillion annually, with $500 billion in Medicare savings. Innovations like home diagnostics and wearables enable early disease detection, allowing for timely interventions….

A federal appeals court has ruled that the Trump administration can continue withholding Medicaid funding from Planned Parenthood and similar health centers while ongoing legal challenges are resolved. This decision affects states that rely on Medicaid for essential healthcare services, including cancer screenings and birth control. The ruling follows multiple lawsuits filed by states and…

Health systems nationwide are deepening their partnerships with Amazon’s One Medical to enhance primary care access and address physician shortages. These collaborations, now beyond pilot stages, are seen as sustainable strategies for digital-first, consumer-oriented care delivery. From Northeast Ohio to the Pacific Northwest, healthcare leaders report patient growth and improved service delivery as key benefits….

Jackson Hospital in Montgomery has filed a lawsuit against Blue Cross Blue Shield of Alabama, alleging that the insurer’s underpayment practices have led to the hospital’s financial instability and bankruptcy. The hospital claims it receives 30-40% less in reimbursements compared to other local facilities, such as Baptist Health. Jackson Hospital is seeking over $250 million…

The FDA is expediting reviews for Merck’s cholesterol pill enlicitide decanoate and cancer therapy sacituzumab tirumotecan under the Commissioner’s National Priority Voucher program. These drugs, with significant sales potential, are expected to be submitted for approval in 2026. The program, launched in June, aims to accelerate drug approvals with critical public health impacts, reducing review…